Pila Pharma Q1’22: New project revealed

Research Note



Redeye leaves its comment on Pila Pharma following the announcement of its Q1 report. Highlights include revealing a new pipeline candidate and certification of API. The financials were broadly in line with expectations.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.